Ipca, Ranbaxy to develop generics for U.S. market

By Lisa Kerner

Charlotte, N.C., Sept. 21 - Ipca Laboratories Ltd. and Ranbaxy Pharmaceuticals Inc. said they have formed a strategic alliance to develop a number of generic prescription pharmaceutical products.

Ranbaxy will market the products in the United States as well as file for regulatory approval and support manufacturing of the products.

Furosemide Tablets 20 mg, 40 mg and 80 mg will be the first products launched as part of the new alliance.

Pharmaceutical company Ipca, based in Maharashtra, India, is preparing a new formulations manufacturing facility to meet U.S. regulatory requirements.

Ranbaxy Pharmaceuticals of Jacksonville, Fla., is a wholly owned subsidiary of the research-based pharmaceutical company Ranbaxy Laboratories Ltd. of Haryana, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.